Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II trials of Sibia's Parkinson's disease Rx begin

Jan. 28, 1998

Allelix: Q1 1998 highlights

Jan. 28, 1998

Antihypertensive efficacy described for Novartis' dual ACE/NEP inhibitor

Jan. 28, 1998

EUK-134 effective in animal model of stroke

Jan. 28, 1998

In vivo efficacy reported for angiotensin II blocker

Jan. 28, 1998

New test for cardiovascular disease risk assessment from Myriad Genetics

Jan. 28, 1998

FDA panel recommends approval of Verdia

Jan. 28, 1998

BioMarin's lead enzyme replacement therapy enters clinical trials

Jan. 28, 1998

Anti-TNF strategy in MS treatment should be reconsidered

Jan. 28, 1998

Rate-independent profile of antiarrhythmic agent suggests improved therapeutic potential

Jan. 28, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...